Skip to main content

Table 1 Clinical and pathological data of the series

From: The lymph node status as a prognostic factor in colon cancer: comparative population study of classifications using the logarithm of the ratio between metastatic and nonmetastatic nodes (LODDS) versus the pN-TNM classification and ganglion ratio systems

  LODDS1
(LODDS ≤ − 2)
LODDS2
(LODDS > − 2 to ≤ − 1)
LODDS3
(LODDS > − 1)
Total P-value
n 349 187 12 548  
Agea 72 (62–79) 73 (64–79) 74 (56–81) 72 (63–80) 0.63
Grouped Age 75 (21.5%) 31 (16.6%) 3 (25%) 109 (19.9%)  
  < 60 140 (40.1%) 79 (42.2%) 3 (25%) 222 (40.5%) 0.53
  > 75 134 (38.4%) 77 (41.2%) 6 (50%) 217 (39.6%)  
Gender
 Female 151 (43.3%) 97 (51.9%) 4 (33.3%) 252 (46%) 0.11
 Male 198 (56.7%) 90 (48.1%) 8 (66.7%) 296 (54%)  
Tumoral Location
 Right colon 128 (36.7%) 61 (32.6%) 6 (50%) 195 (35.6%) 0.73
 Transverse colon 40 (11.5%) 17 (9.1%) 1 (8.3%) 58 (10.6%)  
 Left colon 30 (8.6%) 14 (7.5%) 0 (0%) 44 (8%)  
 Sigmoid colon 129 (37%) 84 (44.9%) 4 (33.3%) 217 (39.6%)  
 Unknown 22 (6.3%) 11 (5.9%) 1 (8.3%) 34 (6.2%)  
Histology
 Adenocarcinoma 300 (86.5%) 151 (81.6%) 10 (83.3%) 461 (84.7%) 0.14
 Mucinous 41 (11.8%) 32 (17.3%) 1 (8.3%) 74 (13.6%)  
 Signet-ring cell 6 (1.7%) 2 (1.1%) 1 (8.3%) 9 (1.7%)  
Major Size (mm)a 45 (30–60) 40 (35–53) 40 (30–50) 45 (32–55) 0.49
Grade
 Unknown 9 (2.6%) 9 (4.8%) 1 (8.3%) 19 (3.5%) 0.025
 I 98 (28.1%) 52 (27.8%) 1 (8.3%) 151 (27.6%)  
 II 227 (65%) 108 (57.8%) 8 (66.7%) 343 (62.6%)  
 III 15 (4.3%) 18 (9.6%) 2 (16.7%) 35 (6.4%)  
Adjuvant Chemotherapy  
 No 262 (75.1%) 103 (55.1%) 6 (50%) 371 (67.7%) <  0.001
 Yes 87 (24.9%) 84 (44.9%) 6 (50%) 177 (32.3%)  
Number retrieved lymph nodesa 12 (8–16) 9 (5–13) 7 (5.5–11) 10 (7–15) <  0.001
Cut-off retrieved lymph nodes
  < 12 178 (51%) 120 (64.2%) 10 (83.3%) 308 (56.2%) 0.002
  ≥ 12 171 (49%) 67 (35.8%) 2 (16.7%) 240 (43.8%)  
Number positive lymph nodesa 0 (0–0) 2 (1–4) 6.5 (4.5–10) 0 (0–1) <  0.001
Lymph Node Ratio      <  0.001
 0–24 349 (100%) 99 (52.9%) 0 (0%) 448 (81.8%)  
 25–60 0 (0%) 80 (42.8%) 0 (0%) 80 (14.6%)  
  > 60 0 (0%) 8 (4.3%) 12 (100%) 20 (3.6%)  
Condensed pT6
 T1–T2 84 (24.1%) 32 (17.1%) 2 (16.7%) 118 (21.5%) 0.16
 T3–T4 265 (75.9%) 155 (82.9%) 10 (83.3%) 430 (78.5%)  
Condensed pN7
 N0 315 (90.3%) 31 (16.6%) 0 (0%) 346 (63.1%) <  0.001
 N1 34 (9.7%) 107 (57.2%) 2 (16.7%) 143 (26.1%)  
 N2 0 (0%) 49 (26.2%) 10 (83.3%) 59 (10.8%)  
Condensed TNM stage
 I 81 (23.3%) 12 (6.4%) 0 (0%) 93 (17%) <  0.001
 II 234 (67%) 19 (10.2%) 0 (0%) 253 (46.2%)  
 III 34 (9.7%) 156 (83.4%) 12 (100%) 202 (36.8%)  
Postoperative Death (90 days)
 No 324 (92.8%) 167 (89.3%) 12 (100%) 503 (91.8%) 0.27
 Yes 25 (7.2%) 20 (10.7%) 0 (0%) 45 (8.2%)  
Follow-up General Mortality
 No 234 (67%) 97 (51.9%) 3 (25%) 334 (60.9%) <  0.001
 Yes 115 (33%) 90 (48.1%) 9 (75%) 214 (39.1%)  
Follow-up Recurrence      0.004
 No 293 (84%) 139 (74.3%) 7 (58.3%) 439 (80.1%)  
 Yes 56 (16%) 48 (25.7%) 5 (41.7%) 109 (19.9%)  
Follow-up Time (months)a 53 (38–66) 46 (17–63) 22 (15–49) 51 (30–64) 0.002
  1. aMedian (IQR: interquartile rang)